

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

e application of: Kashmiri et al.

Application No. 10/519,580

Filed: July 11, 2005 Confirmation No. 3640

HUMANIZED ANTI-TAG 72 CC49 FOR

DIAGNOSIS AND THERAPY OF HUMAN

TUMORS

Examiner: Parithosh K. Tungaturthi

Art Unit: 1643

Attorney Reference No. 4239-66176-05

MAIL STOP AMENDMENT COMMISSIONER FOR PATENTS P.O. BOX 1450 **ALEXANDRIA, VA 22313-1450**

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: MAIL STOP AMENDMENT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below

Attorney or Agent for Applicant(s)

TRANSMITTAL LETTER

Enclosed for filing in the application referenced above are the following:

 \boxtimes Supplemental Information Disclosure Statement

▼ Form 1449

References (4)

 \boxtimes The Director is hereby authorized to charge any additional fees that may be required, or credit over-payment, to Deposit Account No. 02-4550. A copy of this sheet is enclosed.

 \boxtimes Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,

KLARQUIST SPARKMA

Susan Alpert Siegel, Ph.D.

Registration No. 43,121

One World Trade Center, Suite 1600

121 S.W. Salmon Street Portland, Oregon 97204

Telephone: (503) 226-7391 Facsimile: (503) 228-9446

Docketing cc:

MAY 0 5 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

é application of: Kashmiri et al.

Application No. 10/519,580

Filed: July 11, 2005

S:gth

Confirmation No. 3640

HUMANIZED ANTI-TAG 72 CC49 FOR

DIAGNOSIS AND THERAPY OF HUMAN

TUMORS

Examiner: Parithosh K. Tungaturthi

Art Unit: 1643

Attorney Reference No. 4239-66176-05

MAIL STOP AMENDMENT COMMISSIONER FOR PATENTS P.O. BOX 1450 **ALEXANDRIA, VA 22313-1450**

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: MAIL STOP AMENDMENT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent for Applicant(s

Sate Mailed May 3, 2006

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT **PURSUANT TO 37 C.F.R. § 1.97(b)(3)**

Listed on the accompanying form PTO-1449 and enclosed herewith are several Englishlanguage documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Applicants filed this Information Disclosure Statement ("IDS") before the mailing date of a first Office action on the merits. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. Deposit Account authority is provided on the accompanying transmittal letter.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By

Sugar Alpert Siegel, Ph.D. Registration No. 43,121

One World Trade Center, Suite 1600 121 S.W. Salmon Street Portland, Oregon 97204

Telephone: (503) 226-7391 Facsimile: (503) 228-9446

SUPPLE,	MENTAL INFORMATION DISCLOSURE
2 2006	STATEMENT BY APPLICANT

Attorney Docket Number	4239-66176-05
Application Number	10/519,580
Filing Date	July 11, 2005
First Named Inventor	Kashmiri
Art Unit	1643
Examiner Name	Parithosh K. Tungaturthi

Pos con	7		
Initials*	Cite No. (optional)	OTHER DOCUMENTS	
		ADAMS and SCHIER, "Generating improved single-chain Fv molecules for tumor targeting," <i>Journal of Immunological Methods</i> , 231(1-2):249-260, 1999.	
		DE PASCALIS <i>et al.</i> , "In Vitro Affinity Maturation of a Specificity-Determining Region-Grafted Humanized Anticarcinoma Antibody: Isolation and Characterization of Minimally Immunogenic High-Affinity Variants," <i>Clinical Cancer Research</i> , 9(15):5521-5531, 2003.	
		OSBOURN et al., "Generation of a panel of related human scFv antibodies with high affinities for human CEA," <i>Immunotechnology</i> , 2(3):181-196, 1996.	
		Supplementary Partial European Search Report issued on February 27, 2006, for European Patent Application No. EP03762161.2.	

EXAMINER	DATE
SIGNATURE:	CONSIDERED:

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.